Last reviewed · How we verify
Immuno-enhanced
At a glance
| Generic name | Immuno-enhanced |
|---|---|
| Sponsor | Jinling Hospital, China |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ICVAX as a HIV Therapeutic DNA Vaccine (PHASE1)
- REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (PHASE1, PHASE2)
- ERAS Lazio Network Clinical Registry
- AFPᶜ³³²T in Advanced HCC (PHASE1)
- Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
- Immuno-Positron Emission Tomography (PET)-Glioma Study, a Proof-of-principle Imaging Study (NA)
- Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immuno-enhanced CI brief — competitive landscape report
- Immuno-enhanced updates RSS · CI watch RSS
- Jinling Hospital, China portfolio CI